Product Liability

FDA, FTC take aim at fraudulent STD treatments

The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) are taking aim at bogus STD (sexually transmitted diseases) medications that claim to treat a variety of STDs but have never been evaluated by the FDA for safety or efficacy. The agencies want to remove them from the market to prevent consumers from being misled into thinking their condition doesn’t require medical attention.

The fraudulent STD products include brands such as Medavir, Herpaflor, Viruxo, C-Cure, and Never An Outbreak, and claim to treat, cure or prevent diseases such as herpes, Chlamydia, genital wards, HIV and AIDS. They are currently sold online and at retail stores.

The companies who make these products have been warned multiple times by the FDA to remove the drugs from the market and stop making claims they cannot back up; however, they have continued to market and sell the drugs. The agencies have given these drug makers 15 days to report to the FDA of the steps they have taken to correct the violations cited in the warning letters.

The Federal Trade Commission Act states it is illegal to advertise health benefits that are not supported by rigorous scientific evidence.

The FDA Office of Compliance in the agency’s Center for Drug Evaluation and Research says the products are especially dangerous because they are targeting patients with serious conditions where treatment options proven to be safe and effective are currently available. The agency is concerned that patients who use these drugs may not seek the medical attention they need and may be at greater risk for spreading the infection to others.

The agencies say that aggressive enforcement action will continue to be taken against companies that market fraudulent products that may endanger public health.